Cargando…

Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF-κB signaling pathway

Hypertensive disorders may be a complication of pregnancy and are characterized by the high blood pressure. Evidence suggests that alterations in the renin-angiotensin-aldosterone system and the sympathetic nervous system are associated with gestational hypertension. Angiotensin II type 1 receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xudong, Wang, Xietong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059699/ https://www.ncbi.nlm.nih.gov/pubmed/29845261 http://dx.doi.org/10.3892/mmr.2018.9070

Ejemplares similares

Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
por: Choisy, Stéphanie C., et al.
Publicado: (2015)

Candesartan modulates microglia activation and polarization via NF-κB signaling pathway
por: Qie, Shuyan, et al.
Publicado: (2020)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011)

Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer
por: Tabatabai, Ehsan, et al.
Publicado: (2021)

Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity
por: Lin, Wen-Yu, et al.
Publicado: (2022)

Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients
por: Baroroh, Faridah, et al.
Publicado: (2019)

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
por: Lee, Jin Wook, et al.
Publicado: (2023)

Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis
por: Johansen, Thomas Lund, et al.
Publicado: (2001)

Candesartan Cilexetil Improves Angiotensin II Type 2 Receptor–Mediated Neurite Outgrowth via the PI3K-Akt Pathway in Fructose-Induced Insulin-Resistant Rats
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2012)

NF-κB and CREB Are Required for Angiotensin II Type 1 Receptor Upregulation in Neurons
por: Haack, Karla K. V., et al.
Publicado: (2013)

Involvement of angiotensin II receptor type 1/NF-κB signaling in the development of endometriosis
por: Zhang, Zhimin, et al.
Publicado: (2020)

Skeletal muscle insulin resistance in salt-sensitive hypertension: role of angiotensin II activation of NFκB
por: Zhou, Ming-Sheng, et al.
Publicado: (2015)

Transcriptomic Analysis of Mouse Brain After Traumatic Brain Injury Reveals That the Angiotensin Receptor Blocker Candesartan Acts Through Novel Pathways
por: Attilio, Peter J., et al.
Publicado: (2021)

No effect of the angiotensin receptor blocker candesartan on cerebrovascular autoregulation in rats during very high and low sodium intake
por: Sigurdsson, Sigurdur T, et al.
Publicado: (2019)

Expression of Concern: NF-κB and CREB Are Required for Angiotensin II Type 1 Receptor Upregulation in Neurons
Publicado: (2023)

Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011)

Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine-induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway
por: Zhao, Wenxin, et al.
Publicado: (2022)

Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006)

Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor
por: Cha, Seung Ah, et al.
Publicado: (2018)

Salvianolic Acid B-Alleviated Angiotensin II Induces Cardiac Fibrosis by Suppressing NF-κB Pathway In Vitro
por: Wang, Chunhua, et al.
Publicado: (2018)

Up-regulation of angiotensin-converting enzyme in response to acute ischemic stroke via ERK/NF-κB pathway in spontaneously hypertensive rats
por: Ou, Zhou, et al.
Publicado: (2017)

Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
por: Okpechi, Ikechi G, et al.
Publicado: (2010)

Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
por: Granström, Ola, et al.
Publicado: (2012)

In Vitro Vascular-Protective Effects of a Tilapia By-Product Oligopeptide on Angiotensin II-Induced Hypertensive Endothelial Injury in HUVEC by Nrf2/NF-κB Pathways
por: Chen, Jiali, et al.
Publicado: (2019)

Suppression of FPR2 expression inhibits inflammation in preeclampsia by improving the biological functions of trophoblast via NF-κB pathway
por: Li, Shuxian, et al.
Publicado: (2022)

The pivotal role of the angiotensin-II–NF-κB axis in the development of COVID-19 pathophysiology
por: Okamoto, Hiroshi, et al.
Publicado: (2020)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
por: Kjeldsen, S E, et al.
Publicado: (2010)

Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2021)

Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
por: Hajjar, Ihab, et al.
Publicado: (2022)

Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1–7 Signals
por: Kamel, Esam O., et al.
Publicado: (2022)

Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways
por: Xu, Jia-jia, et al.
Publicado: (2021)

Angiotensin II-superoxide-NFκB signaling and aortic baroreceptor dysfunction in chronic heart failure
por: Zhang, Dongze, et al.
Publicado: (2015)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Dual deficiency of angiotensin‐converting enzyme‐2 and Mas receptor enhances angiotensin II‐induced hypertension and hypertensive nephropathy
por: Ni, Jun, et al.
Publicado: (2020)

Attenuation of Angiotensin II–Induced Hypertension in BubR1 Low‐Expression Mice Via Repression of Angiotensin II Receptor 1 Overexpression
por: Aoyagi, Yukihiko, et al.
Publicado: (2019)

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
por: Kim, Jae Hyun, et al.
Publicado: (2014)

Angiotensin II Upregulates Endothelial Lipase Expression via the NF-Kappa B and MAPK Signaling Pathways
por: Zhang, Xiaoli, et al.
Publicado: (2014)

Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5cifsl522kirnc029fsk0is6a